Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1251 daily bars · split adjusted
Current price $0.7891
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| May 19, 26 | Benchmark | maintain | Buy | Speculative Buy |
| May 19, 25 | Benchmark | maintain | Buy | Buy |
| Nov 15, 24 | Benchmark | maintain | Buy | Buy |
| Aug 16, 24 | Benchmark | maintain | Buy | Buy |
| Aug 31, 23 | Benchmark | maintain | Buy | Buy |
| Jul 5, 23 | Benchmark | maintain | Buy | Buy |
| May 15, 23 | Benchmark | maintain | Buy |
Daily · Wilder smoothing
| Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 28.60 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 2.32 | Oscillator | Buy |
| Williams %R (14) | -96.04 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.12 (Hist -0.00) | Oscillator | Strong Sell |
| Average Directional Index (14) | 31.79 (+DI 16.0 / -DI 27.1) | Trend | Strong Sell |
| EMA 20 | 0.92 | MA | Strong Sell |
| SMA 20 | 0.91 | MA | Strong Sell |
| EMA 50 | 1.07 | MA | Strong Sell |
| SMA 50 | 1.21 | MA | Strong Sell |
| SMA 200 | 1.03 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | BFRI | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.3x | -6.9x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -2.0x | EPS est. -0.39 | Elevated |
| Price / Book | 1.7x | 3.0x | Discount |
| Price / Sales | 0.3x | 1.3x | Discount |
| EV / EBITDA | -2.7x | -0.1x | Elevated |
| Return on equity | -127.8% | — | Weak |
| Gross margin | 84.5% | 54.3% | Above hist. |
| Debt / Equity | 1.26 | 0.58 | Moderate |
| Piotroski / Altman Z | 2/9 | Z -6.21 | Distress |
Discounted cash flow model
FY2023 · 10-K disclosure
Stock news · updated daily
Submission seeks to extend the Ameluz ® label beyond the face and scalp to treatment fields of up to approximately 240 cm² on the rest of the body, with an adjusted illumination protocol
Astrazeneca (NYSE: AZN - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Institutional and Insider Ownership 20.4% of Astrazeneca shares are owned
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodynamic therapy platform
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.
WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -0.11 | -0.05 | Beat 52.4% | $12.00M |
| May 14, 2026 | -0.18 | -0.41 | Miss -127.8% | $10.08M |
| Mar 19, 2026 | 0.20 | 0.50 | Beat 156.4% | $17.10M |
| Nov 12, 2025 | -0.60 | -0.59 | Beat 1.7% | $6.99M |
| Aug 13, 2025 | -0.45 | -0.57 | Miss -26.7% | $9.03M |
| May 15, 2025 | -0.22 | -0.47 | Miss -118.6% | $8.59M |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 28, 26 | Luebbert Hermann | director, officer: CEO & Chairman | M-Exempt | 62,500 | — |
| Jul 28, 26 |
| Luebbert Hermann |
| director, officer: CEO & Chairman |
| M-Exempt |
| 62,500 |
| — |
| Jul 28, 26 | Leffler Eugene Frederick | officer: Chief Financial Officer | M-Exempt | 31,250 | — |
| Jul 28, 26 | Leffler Eugene Frederick | officer: Chief Financial Officer | M-Exempt | 31,250 | — |
| Mar 4, 26 | Weber Kevin Daniel | director | A-Award | 20,000 @ $0.90 | $18.00K |
| Mar 5, 26 | Luebbert Hermann | director, officer: CEO & Chairman | M-Exempt | 137,500 | — |
| Mar 4, 26 | Luebbert Hermann | director, officer: CEO & Chairman | A-Award | 125,000 @ $0.90 | $112.5K |
| Mar 4, 26 | Luebbert Hermann | director, officer: CEO & Chairman | A-Award | 125,000 | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Sep 14, 2026 | 2026-09-14 09:29:43 | View |
| 10-Q | Aug 13, 2026 | 2026-08-13 16:41:02 | View |
| 8-K | Aug 13, 2026 | 2026-08-13 09:00:44 | View |
| SC 13G/A | Aug 12, 2026 | 2026-08-12 14:31:34 | View |
| 4 | Jul 29, 2026 | 2026-07-29 17:47:43 | View |
| 4 | Jul 29, 2026 | 2026-07-29 17:44:38 | View |
| S-8 | Jul 22, 2026 | 2026-07-22 17:24:40 | View |
| 10-K/A | Jul 22, 2026 | 2026-07-22 16:40:34 | View |
| 8-K | Jun 17, 2026 | 2026-06-17 16:05:19 | View |
| 10-Q | May 14, 2026 | 2026-05-14 16:28:39 | View |
Proxy statement (DEF 14A) disclosures
